PHILADELPHIA, Nov. 29 /PRNewswire/ -- As part of an ongoing commitment to help clients reduce product development times and maximize commercial impact of their products, Premier Research Group plc (AIM: PRG) announced today the consolidation of its industry-leading expertise in its core service areas into a single group, Strategic Product Development (SPD).
The expertise within the group closely matches Premier Research's focus on clinical research services in neuroscience, analgesia, oncology, infectious disease, and pediatrics. It also reflects the firm's strength in medical device development, adaptive clinical trials design, and state of the art clinical trial related technologies.
"Client demand is driving this," explained Premier Research Group COO Dr. Troy McCall. "Cost and commercialization pressures have our clients focused on leveraging the insights and expertise gained from the hundreds of studies we conduct each year. We're being asked to become involved earlier and more substantively which is great because it leads to better and more efficient studies."
Dr. McCall added that, "Strategic Product Development, in collaboration with a strong Global Regulatory Affairs capability, reflects the company's deep commitment to being a 'solution provider' for our clients. We're routinely told that this philosophy is an important differentiator for us relative to our competitors, and we've dedicated ourselves to continually building upon this strength."
The group will be led by Samer E. Kaba, MD, Vice President, Global
Medical Affairs and SPD and include the following experts:
-- Bernard Brownstein, MD, Vice President, Medical Affairs and SPD --
-- Luciano Fuccella, MD, Vice President, Medical Affairs and SPD --
-- Danielle Giroud, RN, MBA, Vice President, SPD -- Medical Devices
-- Sid Jevons, PhD, Vice President, SPD -- Infectious Diseases
|SOURCE Premier Research Group plc|
Copyright©2007 PR Newswire.
All rights reserved